23andMe Develops Drug Compound Using Consumer Genetic Data
23andMe, a consumer genetics company, has licensed its first drug compound to Almirall, a global pharmaceutical company.
All articles by Steve Duffy
Haymarket Medical Education Receives Interprofessional Joint Accreditation for the Healthcare Team
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
Berotralstat NDA for Hereditary Angioedema Prophylaxis Submitted to FDA
The New Drug Application for berotralstat for the prevention of hereditary angioedema attacks has been submitted to the Food and Drug Administration.
Second Trial Confirms Efficacy of Bimekizumab in Plaque Psoriasis
Bimekizumab (UCB), an investigational treatment for moderate-to-severe plaque psoriasis, met its two primary end points in a second phase 3 trial.
Hydrogen Peroxide Topical Solution Clears Common Warts in Phase 3 Trial
Aclaris Therapeutics announced positive results from a phase 3 trial investigating a proprietary formulation of hydrogen peroxide (A-101) for the topical treatment of common warts.
NDA Submitted for First-in-Class Acne Cream
Clascoterone is a topical androgen receptor inhibitor.
Guselkumab Superior to Secukinumab in Plaque Psoriasis Trial
According to results from the ECLIPSE trial, treatment with guselkumab was found to be superior to secukinumab in adult patients with moderate-to-severe plaque psoriasis based on 90% or better improvement in patients’ Psoriasis Area and Severity Index score compared to baseline (PASI 90 response).
NDA for Investigational Rosacea Treatment Submitted to FDA
FMX103 is a topical foam formulation of the antibiotic minocycline.
FDA Recalls Herbal Medications Being Marketed for Various Diseases
In addition to being manufactured outside of the controls required by current Good Manufacturing Practices, these products are also being marketed for diseases without FDA approval.
NDA Submitted for Novel Epithelioid Sarcoma Treatment
Epizyme has submitted a New Drug Application (NDA) for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
Next post in General Dermatology
